Publication | Open Access
An investigation of the safety and pharmacokinetics of the novel TRPV1 antagonist XEN‐D0501 in healthy subjects
62
Citations
23
References
2011
Year
XEN-D0501 appeared safe and well tolerated at doses up to 5 mg twice daily for 14 days in healthy subjects.
| Year | Citations | |
|---|---|---|
Page 1
Page 1